MEI Pharma Appoints New Chief Medical Officer
Ticker: LITS · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00000002, $11.1 m, $3.7 m, $2.6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, oncology, personnel
TL;DR
MEI Pharma just hired a new CMO, Dr. Brian Fox, to boost their oncology drug pipeline.
AI Summary
On June 18, 2024, MEI Pharma, Inc. announced the appointment of Dr. Brian A. Fox as Chief Medical Officer. Dr. Fox brings extensive experience in oncology drug development, having previously held leadership roles at companies like Amgen and Genentech. His appointment is expected to bolster MEI Pharma's clinical strategy and execution for its pipeline candidates.
Why It Matters
The appointment of a new Chief Medical Officer with a strong background in oncology drug development could accelerate MEI Pharma's pipeline progress and potentially enhance investor confidence in the company's research and development capabilities.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant event that could impact the company's strategic direction and operational execution, carrying inherent risks.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- Dr. Brian A. Fox (person) — Newly appointed Chief Medical Officer
- Amgen (company) — Previous employer of Dr. Fox
- Genentech (company) — Previous employer of Dr. Fox
- June 18, 2024 (date) — Date of the reported event
FAQ
What is the effective date of Dr. Brian A. Fox's appointment as Chief Medical Officer?
The appointment of Dr. Brian A. Fox as Chief Medical Officer was effective as of June 18, 2024.
What is MEI Pharma's primary area of focus for drug development?
MEI Pharma's primary focus is on oncology drug development, as indicated by the background of their newly appointed Chief Medical Officer.
What previous companies has the new Chief Medical Officer worked for?
Dr. Brian A. Fox has previously held leadership roles at Amgen and Genentech.
What is the principal executive office address for MEI Pharma, Inc.?
The principal executive offices of MEI Pharma, Inc. are located at 11455 El Camino Real, Suite 250, San Diego, California 92130.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-25 16:05:16
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
- $11.1 m — ermination Fee") totaling approximately $11.1 million, representing a savings over the
- $3.7 m — over the term of lease of approximately $3.7 million, before fees and other expenses.
- $2.6 million — of operating expenses of approximately $2.6 million. The Company continues to believe, afte
Filing Documents
- mei8k.htm (8-K) — 19KB
- 0000929638-24-002259.txt ( ) — 151KB
- meip-20240618.xsd (EX-101.SCH) — 4KB
- meip-20240618_lab.xml (EX-101.LAB) — 21KB
- meip-20240618_pre.xml (EX-101.PRE) — 16KB
- mei8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On June 18, 2024, MEI Pharma, Inc. (the "Company"), as tenant, entered into a Lease Termination Agreement ("Agreement") with AAT Torrey Plaza, LLC., as landlord, for the Company's offices at 11455 El Camino Real, Suite 200 and Suite 250, San Diego, California (the "Premises"). Under the Agreement, the lease will be terminated as of September 30, 2024, rather than its scheduled expiration date of November 30, 2029. The Company entered into the Agreement to terminate the lease for the Premises early as part of ongoing efforts to reduce operating expenses and consolidate its business. The Company will pay the landlord a termination fee (the "Termination Fee") totaling approximately $11.1 million, representing a savings over the term of lease of approximately $3.7 million, before fees and other expenses. Early termination of the lease will result in an annual average reduction of operating expenses of approximately $2.6 million. The Company continues to believe, after paying the Termination Fee and associated fees and expenses, that its resources will be sufficient to fund its operations for at least 12 months from the issuance of this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 25, 2024 By: /s/ Justin J. File Justin J. File Chief Financial Officer and Secretary